Cardiff Oncology, Inc. (CRDF)
NASDAQ: CRDF · Real-Time Price · USD
2.505
-0.025 (-0.99%)
Nov 21, 2024, 2:54 PM EST - Market open
Cardiff Oncology Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Cardiff Oncology stock have an average target of 9.33, with a low estimate of 7.00 and a high estimate of 13. The average target predicts an increase of 272.46% from the current stock price of 2.51.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CRDF stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $14 → $13 | Strong Buy | Maintains | $14 → $13 | +418.96% | Nov 8, 2024 |
| Craig-Hallum | Craig-Hallum | Strong Buy Initiates $8 | Strong Buy | Initiates | $8 | +219.36% | Sep 6, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $14 | Strong Buy | Reiterates | $14 | +458.88% | May 6, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $12 → $14 | Strong Buy | Maintains | $12 → $14 | +458.88% | Mar 6, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $5 → $7 | Buy | Maintains | $5 → $7 | +179.44% | Mar 1, 2024 |
Financial Forecast
Revenue This Year
561.20K
from 488.00K
Increased by 15.00%
Revenue Next Year
328.44K
from 561.20K
Decreased by -41.48%
EPS This Year
-1.03
from -0.93
EPS Next Year
-1.06
from -1.03
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 822,150 | 1.1M | 420,000 | ||
| Avg | 561,204 | 328,440 | 135,997 | ||
| Low | 392,000 | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 68.5% | 89.1% | 27.9% | ||
| Avg | 15.0% | -41.5% | -58.6% | ||
| Low | -19.7% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.04 | -0.84 | -1.21 | ||
| Avg | -1.03 | -1.06 | -1.35 | ||
| Low | -1.02 | -1.20 | -1.48 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.